American Journal of Cardiology
Volume 108, Issue 7 , Pages 905-911 , 1 October 2011

Efficacy and Safety of Intensive Antiplatelet Therapy With Prasugrel from TRITON-TIMI 38 in a Core Clinical Cohort Defined by Worldwide Regulatory Agencies

  • Stephen D. Wiviott, MD

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 617-278-0145; fax: 617-734-7329
    • ,
  • Nihar Desai, MD

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
    • ,
  • Sabina A. Murphy, MPH

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
    • ,
  • Guiseppe Musumeci, MD

      Affiliations

    • Cardiovascular Department, Ospedali Riuniti, Bergamo, Italy
    • ,
  • Michael Ragosta, MD

      Affiliations

    • University of Virginia Health System, Charlottesville, Virginia
    • ,
  • Elliott M. Antman, MD

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
    • ,
  • Eugene Braunwald, MD

      Affiliations

    • The TIMI Study Group, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts

Received 7 February 2011 ,Revised 9 May 2011 ,Accepted 9 May 2011.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 The TRITON-TIMI 38 trial was supported by Daiichi Sankyo Company, Limited and Eli Lilly and Company. Drs. Wiviott, Antman, and Braunwald report receiving research grants from Daiichi Sankyo, Parsippany, New Jersy, Eli Lilly, Indianapolis, Indiana, Sanofi-Aventis, Merck, and Schering Plough.

PII: S0002-9149(11)01906-0

doi: 10.1016/j.amjcard.2011.05.020

American Journal of Cardiology
Volume 108, Issue 7 , Pages 905-911 , 1 October 2011

Article Tools

* Image Usage & Resolution